Member Info for Bobbler

Nice open so far

Based on the last 10 days, I would say anyone’s guess.

Wow, you really are a concerning individual.

Classic123…….. stalker and clown, concerning combo.

Positive and logical opinion. So much better than pointless negativity

Potnak I agree, and maybe I’m reading this wrong…
“ The Company aims to commence Phase 1 clinical trials for SDC-1801 in early 2022”

The reasons why I don’t believe the above sentence relates to Covid, and I may be incorrect on these assumptions so please correct me if I am.

1. Sar couldn’t commence phase 1 clinical trials in relation to Covid without U.K. gov support.

2. If the sentence relates to Covid then wouldn’t they say “we’ve secured funding and we’re entering the agile trial, with plans to start early 2022”.

Potnak, I will politely disagree. If you read the Covid update RNS:

“Subject to successful completion of the ongoing preclinical toxicology studies, requisite approvals and financing, the Company aims to commence Phase 1 clinical trials for SDC-1801 in early 2022. The timing and design of the clinical trials for Covid-19 applications will be determined following consultations with experts in the field.”

The final sentence (in my opinion) clearly states that they intend to run to separate trials. Otherwise why state:

“The timing and design of the clinical trials for Covid-19 applications will be determined following consultations with experts in the field.

If it’s the same clinical trial why repeat the statement?

https://www.bbc.co.uk/news/health-58307215

"While we continue to build this wall of defence from Covid-19, it's also vital we do everything we can to protect the country for the future too - whether that's from the virus as we know it or new variants," he said.“

Can’t see potential therapeutics being ignored

My take is that Gov Covid trial funding is secured and it’s now a matter of clarification with regards to trial design.

If you reread the RNS from Mon, 9th Aug 2021 13:26

“Clinical trial plans, including priority autoimmune indications and potential Covid-19 application, will also be developed in parallel, subject to additional funding being raised.”

Note subject to funding.

Then the latest trading update RNS:

“The Company aims to commence Phase 1 clinical trials for SDC-1801 in early 2022, subject to successful completion of the ongoing preclinical toxicology studies, gaining the requisite approval and financing. ( new sentence) The timing and design of the clinical trials for Covid-19 applications will be determined following consultations with experts in the field.”

No mention of subject to funding ref Covid.
Also of interest is the earlier RNS states “POTENTIAL” Covid applications, whereas the latter does not use the word potential, simply Covid-19 applications.

Just my observations.

Potnak; I don’t think the BOD are in a position say anymore than they have ref Covid applications.

“The timing and design of the clinical trials for Covid-19 applications will be determined following consultations with experts in the field.”

That suggests that they are waiting on others, most probably those overseeing the various trials.

Personally I still think they are progressing as planned with a U.K. gov trial platform. The lead prof of the U.K. Agile trials was also a contributor to the
GenOMICC (Genetics Of Mortality In Critical Care) genome-wide association study in 2,244 critically ill patients with COVID-19 from 208 UK intensive care units, the subsequent Nature article that highlighted tyk2 was the springboard.

The science hasn’t changed and I’m yet to see a valid argument or reason why they would suddenly drop any promisingly treatment for c19.

Bearded Dragon. Quick explanation without going into the technical scientific aspects. When the cadre of clowns show up it’s generally because they are trying to drive the price down further. This has subsequently been followed by good news and a rise in SP. if your a chart/equation person put the following into your software: womble, clown, chickens male counterpart. The equation should produce the following user names: classic123, senator bum time and tiny Trimme.

When bumtime and the classic clown are in town we normally see a rise.

This review focuses on the growing evidence from genomic and proteomic screens, as well as molecular studies that link TYK2 to cancer prevalence, prognosis, and metastasis. In addition, pharmacological inhibition of TYK2 is currently used clinically for autoimmune diseases, and now provides promising treatment modalities as effective therapeutic agents against multiple types of cancer.

Great post! Now for some positive posts :-)

Disagree £50k for nothing

A good one, they’ve all be good in 2021

I think we may see a 11.14am RNS.
Just a feeling

Well they confirmed that there were additional HNWI “ subscriptions to two additional high net worth individuals plus an exercise of warrants.

Also like this statement :

“ build a robust data package to support our ongoing partnering activities for these exciting and differentiated assets."

Beforegolf. Personally I couldn’t give 2 ducks.

Footnote: however our HNWI’s are happy to place bets of £1m plus………..